Inhibikase Therapeutics Inc. (IKT)
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN 
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Up 52.2% in February
Inhibikase Therapeutics, Inc. (NASDAQ: IKT - Get Free Report) was the target of a significant increase in short interest in the month of February. As of February 27th, there was short interest totaling 16,041,114 shares, an increase of 52.2% from the February 12th total of 10,541,776 shares. Based on an average daily trading volume, of 3,478,233
Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Inhibikase Therapeutics (IKT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study
Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating and walking in a mid-stage study.
Inhibikase: Potential To Improve Current Treatment Options For PAH Patients
The company received FDA approval to initiate a late-stage study of IKT-001Pro for pulmonary arterial hypertension, backed by $275 million in funding. IKT-001Pro, a modified version of imatinib, aims to treat PAH with fewer side effects, leveraging Inhibikase's RAMP drug innovation engine. Risvodetinib, targeting untreated Parkinson's Disease, is in a phase 2 study with top-line data expected in Q4 2024, presenting a catalyst opportunity.
Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript
Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q2 2024 Earnings Conference Call August 15, 2024 8:00 AM ET Company Participants Alexander Lobo - Precision AQ, Investor Relations Milton Werner - President and Chief Executive Officer Garth Lees-Rolfe - Chief Financial Officer Conference Call Participants Jason McCarthy - Maxim Group Edward White - H.C. Wainwright Operator Greetings and welcome to the Inhibikase Therapeutics Second Quarter 2024 Financial Results Conference Call.
Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript
Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q1 2024 Earnings Conference Call May 16, 2024 8:00 AM ET Company Participants Alexander Lobo - Stern Investor Relations Milton Werner - CEO Garth Lees-Rolfe - CFO Conference Call Participants Ed White - H.C. Wainwright Operator Greetings and welcome to Inhibikase Therapeutics First Quarter 2024 Financial Results Conference Call.
